drugset / Trial / NCT00801684

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

NCT00801684

Phase 2 Completed 24 enrolled Alkermes, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).

Timeline

Start
2009-02
Primary completion
2009-04
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 12 ug Inhaled
Subject Trospium Small molecule 100 ug Inhaled
Subject Trospium Small molecule 400 ug Inhaled